Association of HLA Class II Alleles with Disease Severity and Treatment Response in Iranian Patients with Myasthenia Gravis-Reference-Cited by-同舟云学术

Association of HLA Class II Alleles with Disease Severity and Treatment Response in Iranian Patients with Myasthenia Gravis

Published:2021-09-14 Issue:5 Volume:8 Page:827-829
ISSN:2214-3599
Container-title:Journal of Neuromuscular Diseases
language:
Short-container-title:JND

Author:

Sinaei Farnaz¹,Fatehi Farzad¹,Oveis Gharan Shahram¹²,Ehsan Soroush¹,Kamali Koorosh³,Amirzargar Aliakbar⁴⁵,Mahmoudi Mahdi⁶,Vaghefifar Alaleh¹,Nafissi Shahriar¹

Affiliation:

1. Department of Neurology, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran

2. Rush Alzheimer Disease Center, Rush University Medical Center, Chicago, IL, USA

3. Department of Public Health, School of Public Health, Zanjan University of Medical Sciences, Zanjan, Iran

4. Molecular Immunology Research Center, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran

5. Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran

6. Rheumatology Research center (RRC), Shariati hospital, Tehran University of Medical Sciences, Tehran, Iran

Abstract

Myasthenia gravis is an autoimmune neuromuscular disease with a multifactorial etiology. A major part of the genetic susceptibility belongs to the HLA encoding genes. In this study, we investigated the role of HLA class II polymorphism in disease severity, and treatment response. In our 146 patients, 15 DRB1, 7 DQA1, and 9 DQB1 alleles, and 19 haplotypes were found. Adjusted p-values did not show any significant associations between these loci, disease severity and treatment outcome. Further studies in different populations with a larger number of patients are needed to determine the exact contribution of HLA class II alleles to MG prognosis.

Publisher

IOS Press

Subject

Neurology (clinical),Neurology

Reference8 articles.

1. Li H-F , Hong Y , Xie Y , Hao H-J , Sun R-C . Precision medicine in myasthenia graves: Begin from the data precision. Annals of Translational Medicine. 2016;4(6).

2. The immunogenetics of neurological disease;Misra;Immunology,2018

3. Association of HLA class II (DRB1, DQA1, DQB1) alleles and haplotypes with myasthenia gravis and its subgroups in the Iranian population;Ehsan;Journal of the Neurological Sciences,2015

4. Myasthenia gravis: Recommendations for clinical research standards;Jaretzki;Neurology,2000

5. Pharmacogenomic Biomarkers for Improved Drug Therapy—Recent Progress and Future Developments;Lauschke;AAPS Journal,2017

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. HLA-genotyping by next-generation-sequencing reveals shared and unique HLA alleles in two patients with coexisting neuromyelitis optica spectrum disorder and thymectomized myasthenia gravis: Immunological implications for mutual aetiopathogenesis?;Multiple Sclerosis and Related Disorders;2022-07